Alternative splicing in disease and therapy

Mariano A. Garcia-Blanco, Andrew P. Baraniak, Erika L. Lasda

Research output: Contribution to journalReview article

405 Scopus citations

Abstract

Alternative splicing is the major source of proteome diversity in humans and thus is highly relevant to disease and therapy. For example, recent work suggests that the long-sought-after target of the analgesic acetaminophen is a neural-specific, alternatively spliced isoform of cyclooxygenase 1 (COX-1). Several important diseases, such as cystic fibrosis, have been linked with mutations or variations in either cis-acting elements or trans-acting factors that lead to aberrant splicing and abnormal protein production. Correction of erroneous splicing is thus an important goal of molecular therapies. Recent experiments have used modified oligonucleotides to inhibit cryptic exons or to activate exons weakened by mutations, suggesting that these reagents could eventually lead to effective therapies.

Original languageEnglish (US)
Pages (from-to)535-546
Number of pages12
JournalNature Biotechnology
Volume22
Issue number5
DOIs
StatePublished - May 1 2004
Externally publishedYes

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Molecular Medicine
  • Biomedical Engineering

Fingerprint Dive into the research topics of 'Alternative splicing in disease and therapy'. Together they form a unique fingerprint.

  • Cite this